Original Article "TREATMENT SUCCESS OF SOFOSBUVIR AND DACLATSVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS OF HEPATITIS C VIRUS"

Abstract

ABSTRACT

Objective: To compare the frequency of responders achieving SVR12 after taking sofosbuvir and daclatasvir with vs without ribavirin

Study Setting: It was conducted in the department of medicine, Government Teaching Hospital Shahdara, Lahore.

Study Duration: From March 25, 2021 to September 24, 2021

Study Design: Randomized controlled trial.

Material and Methods:Total 180 patients meeting inclusion criteria were enrolled in study. Treatment naive cases were given tablet sofosbuvir&daclatasvir for a period of 12 weeks. Treatment experienced and naive with cirrhosis were given ribavirin based on their body weight along with sofosbuvir and daclatasvir for a period of 12 weeks. After 3 months treatment, patients were called for follow up at 12^th week post-treatment for HCV RNA PCR to see if patient has achieved SVR12 or not. Statistical analysis was performed using SPSS v25.0. Frequency of responders was compared using Chi-square test. P-value less than or equal to 0.05 was considered statistically significant.

Results: In group-A, 54(60.0%) patients were males and 36(40%) patients were females. In group-B, 52(57.8%) patients were males and 38(42.2%) were females. The mean age in patients of group-A was 45.69±12.481 years while that was 44.99±14.590 years in group-B. In group-A (Sofosbuvir and daclatasvir with ribavirin), 81(90.0%) patients had response rate and in group-B (Sofosbuvir and daclatasvir), 65(72.2%) patients had response rate with p-value (p=0.002).

Conclusion: It was concluded that sofosbuvir&daclatasvir with ribavirin was found more efficacious than sofosbuvir&daclatasvir alone in achieving SVR 12 in patients of chronic hepatitis C infection, so it will help in delaying disease process and improving quality of life especially in the developing world.

KEYWORDS:                        Sofosbuvir, Daclatasvir, Ribavirin, Hepatitis C.